Fertility and Perinatal/Postnatal Studies in Rats with the Antiarrhythmic Agent Pirmenol
Tóm tắt
Fertility and perinatal/postnatal studies were conducted in Sprague-Dawley rats with the Class Ia antiarrhythmic agent pirmenol. Doses of 25, 50 or 100 mg/kg/day were administered in the diet for both studies; untreated control groups received basal diet. Male rats in the fertility study were treated for 75 days prior to mating, while F0 female rats were treated for 15 days prior to mating, and also during mating, gestation and lactation. F0 female rats in the perinatal/postnatal study were treated from gestation day (GD) 15 to lactation day 21. Caesarean section was performed on half the fertility study females per group on GD 20, while the remaining half of the fertility study females and all perinatal/postnatal study females were allowed to deliver and raise the F1 offspring. The F1 generation was evaluated for survival, growth, development, behaviour and reproductive performance. Although bodyweight and food consumption of fertility study F0 parents were reduced at pirmenol 100 mg/kg/day, no treatment-related effects were observed on reproductive parameters, or on maternal and fetal parameters evaluated at caesarean section. Reduction in bodyweight occurred for fertility study F1 offspring of all treatment groups during the neonatal period, but not during maturation. Offspring were unaffected with regard to survival, development, behaviour or reproductive performance. Treatment-related effects observed in perinatal/postnatal study F1 females at pirmenol 50 and/or 100 mg/kg/day included clinical signs of toxicity, reduction of bodyweight gain and food consumption, and stomach lesions. Food spillage, indicative of a possible palatability problem, also occurred at 100 mg/kg. Viability of F1 offspring was decreased at 100 mg/kg/day, while the incidence of dilated renal pelvis was increased; treatment-related reduction of bodyweight and open field activity occurred at pirmenol 50 and 100 mg/kg/day. Results of these studies indicate that the nature, magnitude and duration of pirmenol-related effects differed according to treatment regimen.
Tài liệu tham khảo
Anderson JA, Petrere JA, Fitzgerald JE, de la Iglesia FA. Studies on reproduction in rats with pirmenol, an antiarrhythmic agent. Fundamental and Applied Toxicology 7: 221–227, 1986
Barlow SM, Knight AF, Sullivan FM. Delay in postnatal growth and development of offspring produced by maternal restraint stress-during pregnancy in the rat. Teratology 18: 211–218, 1978
Chang T. Preclinical and clinical pharmacokinetics of pirmenol. American Journal of Cardiology 59: 15H–19H, 1987
Cripps AW, Williams VJ. The effect of pregnancy and lactation on food intake, gastrointestinal anatomy and the absorptive capacity of the small intestine in the albino rat. British Journal of Nutrition 33: 17–32, 1975
Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association 50: 1096–1121, 1955
Dunnett CW. New tables for multiple comparisons with a control. Biometrics 20: 482–491, 1964
Gad SC, Weil CS. Statistics and experimental design for toxicologists, pp. 70–92, Telford Press, Caldwell, New Jersey, 1986
Guide for the care and use of laboratory animals. NIH Publication 86-23, 1985
Johnson BF, Shekar V, Woodman T, Canada AT. Salivary concentrations of pirmenol as a possible cause of unpleasant taste. British Journal of Clinical Pharmacology 22: 613–615, 1986
Kaplan HR, Mertz TE, Steife TJ. Pirmenol: preclinical pharmacology. Angiology 39: 281–292, 1988
Kivilaakso E. Pathogenetic mechanisms in experimental gastric stress ulceration. Scandinavian Journal of Gastroenterology 110 (Suppl.): 57–62, 1985
Koski KG, Hill FW. Evidence for a critical period during late gestation when maternal dietary carbohydrate is essential for survival of newborn rats. Journal of Nutrition 120: 1016–1027, 1990
Liem LB, Kates RE. Update: cardiac antiarrhythmic drugs. Comprehensive Therapy 15: 17–27, 1989
Macallum GE, Smith GS. Tumorigenicity studies of pirmenol in rats and mice. Toxicologist 10: 149, 1990
Maurissen JPJ, Mattsson JL. Critical assessment of motor activity as a screen for neurotoxicity. Toxicology and Industrial Health 5: 195–202, 1989
Mitani GM, Steinberg I, Lien EJ, Harrison EC, Elkayam U. The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clinical Pharmacokinetics 12: 253–291, 1987
Rotmensch HH, Rotmensch S, Elkayam U. Management of cardiac arrhythmias during pregnancy — current concepts. Drugs 33: 623–633, 1987
Schardein JL, Fitzgerald JE, Sanyer JL, McGuire EJ, de la Iglesia FA. Preclinical toxicology studies with a new antiarrhythmic agent: pirmenol hydrochloride (CI-845). Toxicology and Applied Pharmacology 56: 294–301, 1980
Scialli AR. Is stress a developmental toxin? Reproductive Toxicology 1: 163–171, 1988
Staples RE. Detection of visceral alterations in mammalian fetuses. Teratology 9: 37–38, 1974
Staples RE, Schnell VL. Refinements in rapid clearing technic in the KOH-alizarin red S method for fetal bone. Stain Technology 39: 61–63, 1964
Wilson JG. Embryological considerations in teratology. In Wilson & Warkany (Eds) Teratology: principles and techniques, pp. 251–277, University of Chicago Press, Chicago, 1965
Woo DC, Hoar RM. ‘Apparent hydronephrosis’ as a normal aspect of renal development in late gestation of rats: the effect of methyl salicylate. Teratology 6: 191–196, 1972